| Literature DB >> 28233834 |
Robin Myte1, Björn Gylling2, Jenny Häggström3, Jörn Schneede4, Per Magne Ueland5, Göran Hallmans6, Ingegerd Johansson7, Richard Palmqvist2, Bethany Van Guelpen1.
Abstract
The role of one-carbon metabolism (1CM), particularly folate, in colorectal cancer (CRC) development has been extensively studied, but with inconclusive results. Given the complexity of 1CM, the conventional approach, investigating components individually, may be insufficient. We used a machine learning-based Bayesian network approach to study, simultaneously, 14 circulating one-carbon metabolites, 17 related single nucleotide polymorphisms (SNPs), and several environmental factors in relation to CRC risk in 613 cases and 1190 controls from the prospective Northern Sweden Health and Disease Study. The estimated networks corresponded largely to known biochemical relationships. Plasma concentrations of folate (direct), vitamin B6 (pyridoxal 5-phosphate) (inverse), and vitamin B2 (riboflavin) (inverse) had the strongest independent associations with CRC risk. Our study demonstrates the importance of incorporating B-vitamins in future studies of 1CM and CRC development, and the usefulness of Bayesian network learning for investigating complex biological systems in relation to disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28233834 PMCID: PMC5324061 DOI: 10.1038/srep43434
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1One-carbon metabolism.
Graphical representation of the main aspects of one-carbon metabolism centered around the folate and methionine cycles. Abbreviations: BHMT, betaine homocysteine S- methyltransferase; CBS, cystathionine β-synthase; CH2THF, 5,10-methylenetetrahydrofolate; CH3THF, 5-methyltetrahydrofolate; CHOTHF, formyltetrahydrofolate; CHTHF, methenyltetrahydrofolate; CTH, cystathionine γ-lyase (also abbreviated CSE); DHF, dihydrofolate; DHFR, dihydrofolate reductase; dTMP, deoxythymidine 5′-monophosphate; dUMP, deoxyuridine 5′-monophosphate; FOLR, folate receptor; MTHFD, methylenetetrahydrofolate dehydrogenase; MTHFR, 5,10-methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; RFC, reduced folate carrier; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SHMT, serine hydroxymethyltransferase; TCN2, Transcobalamin II; THF, tetrahydrofolate; TYMS, thymidylate synthase.
Baseline characteristics.
| Cases (n = 613) | Controls (n = 1190) | P | Missing (%) | ||||
|---|---|---|---|---|---|---|---|
| N | Median (IQR | N | Median (IQR | ||||
| Age at sampling (years) | 613 | 59.8 (40.1–67.8) | 1190 | 59.7 (40.0–67.8) | 0 | ||
| Sex, female | 360 | 59% | 703 | 59% | 0 | ||
| Cohort, VIP | 479 | 78% | 931 | 78% | 0 | ||
| Fasting status | 0 | ||||||
| <4 hours | 141 | 23% | 272 | 23% | |||
| 4–8 hours | 107 | 17% | 202 | 17% | |||
| ≥8 hours | 365 | 60% | 716 | 60% | |||
| Smoking status | 0 | ||||||
| Current | 114 | 19% | 239 | 20% | 0.01 | ||
| Ex- | 136 | 22% | 197 | 17% | |||
| Never | 363 | 59% | 754 | 63% | |||
| Body mass index (BMI, kg/m2) | 591 | 25.7 (23.5–28.2) | 1147 | 25.6 (23.3–28.1) | 0.43 | 4 | |
| Alcohol intake (g/day) | 385 | 2.4 (0.2–5.8) | 754 | 2.3 (0.3–5.7) | 0.94 | 13 | |
| Recreational physical activity | 3 | ||||||
| 1 | 221 | 45% | 354 | 40% | 0.92 | ||
| 2 | 117 | 25% | 240 | 27% | |||
| 3 | 81 | 17% | 168 | 19% | |||
| 4 | 29 | 6% | 68 | 7% | |||
| 5 | 30 | 7% | 64 | 7% | |||
| Occupational physical activity | 0.94 | 13 | |||||
| 1 | 90 | 21% | 163 | 20% | |||
| 2 | 77 | 18% | 155 | 19% | |||
| 3 | 111 | 27% | 223 | 27% | |||
| 4 | 102 | 25% | 229 | 28% | |||
| 5 | 36 | 9% | 45 | 6% | |||
| eGFR (ml/min/1.73 m2) | 596 | 62.0 (52.3–73.0) | 1149 | 61.7 (50.9–72.3) | 0.48 | 4 | |
| Neopterin (nmol/L) | 608 | 9.7 (8.2–11.9) | 1186 | 9.4 (8.0–11.4) | 0.02 | 0.5 | |
| KTr | 613 | 0.023 (0.019–0.026) | 1190 | 0.022 (0.019–0.026) | 0.23 | 0 | |
| Vitamin supplement use | 0 | ||||||
| Last 14 days | 32 | 7% | 73 | 8% | 0.49 | ||
| Last year | 40 | 8% | 105 | 11% | 0.11 | ||
| Folate (μg/MJ) | 359 | 29.9 (25.3–36.0) | 697 | 29.8 (25.3–36.0) | 0.81 | 6 | |
| Vitamin B6 (mg/MJ) | 359 | 0.27 (0.22–0.31) | 697 | 0.26 (0.23–0.30) | 0.98 | 6 | |
| Vitamin B2 (riboflavin, mg/MJ) | 359 | 0.19 (0.16–0.22) | 697 | 0.19 (0.16–0.22) | 0.38 | 6 | |
| Vitamin B12 (cobalamin, μg/MJ) | 359 | 0.61 (0.46–0.78) | 697 | 0.59 (0.48–0.78) | 0.89 | 6 | |
| Folate (nmol/L) | 613 | 7.3 (4.9–10.4) | 1190 | 7.2 (4.6–10.2) | 0.49 | 0 | |
| Vitamin B6 (PLP, nmol/L) | 608 | 35.9 (25.9–51.5) | 1186 | 38.2 (28.0–51.5) | 0.08 | 0.5 | |
| Vitamin B2 (riboflavin, nmol/L) | 608 | 10.8 (7.4–16.0) | 1186 | 11.8 (7.9–17.9) | 0.002 | 0.5 | |
| Vitamin B12 (cobalamin, nmol/L) | 603 | 413 (337–498) | 1173 | 426 (353–501) | 0.02 | 2 | |
| Homocysteine (μmol/L) | 613 | 10.1 (8.4–11.9) | 1190 | 9.9 (8.2–11.7) | 0.15 | 0 | |
| Cystathionine (μmol/L) | 613 | 0.15 (0.12–0.21) | 1190 | 0.16 (0.12–0.22) | 0.65 | 0 | |
| Cysteine (μmol/L) | 613 | 275 (253–299) | 1190 | 276 (255–298) | 0.74 | 0 | |
| Glycine (μmol/L) | 613 | 227 (194–265) | 1190 | 225 (194–277) | 0.96 | 0 | |
| Serine (μmol/L) | 613 | 108 (96–122) | 1190 | 110 (96–124) | 0.43 | 0 | |
| Methionine (μmol/L) | 613 | 25.9 (23.2–29.1) | 1190 | 26.4 (23.4–29.9) | 0.07 | 0 | |
| Choline (μmol/L) | 606 | 8.6 (7.6–9.7) | 1189 | 8.6 (7.6–9.8) | 0.83 | 0.4 | |
| Betaine (μmol/L) | 606 | 29.9 (25.7–34.4) | 1189 | 30.8 (26.1–35.5) | 0.05 | 0.4 | |
| DMG (μmol/L) | 606 | 3.6 (2.9–4.4) | 1189 | 3.6 (3.0–4.4) | 0.79 | 0.4 | |
| Sarcosine (μmol/L) | 613 | 1.5 (1.1–2.0) | 1190 | 1.5 (1.2–2.1) | 0.54 | 0 | |
| Age at diagnosis (years) | 613 | 65.2 (59.3–70.2) | 0 | ||||
| Follow-up time (years) | 613 | 8.2 (4.7–11.9) | 0 | ||||
| Tumor site | 0.2 | ||||||
| Right colon | 183 | 30% | |||||
| Left colon | 215 | 35% | |||||
| Rectum | 214 | 35% | |||||
| Tumor stage | 5 | ||||||
| I-II | 308 | 53% | |||||
| III-IV | 276 | 47% | |||||
Abbreviations: PLP, pyridoxal 5′ phosphate – DMG, Dimethylglycine – MJ, Mega Joules – eGFR, estimated glomerular filtration rate (by Cockcroft–Gault formula) – KTr, kynurenine/tryptophan ratio.
aIQR: Interquartile range (25th-75th percentile).
bFrom test for difference in distribution between cases and controls. Mann-Whitney U tests for continuous variables, Chi-square tests for categorical variables. Not calculated for matching variables. Bonferroni-corrected threshold for significance differences among metabolites = 0.05/14 ≈ 0.004.
cVariables available in the VIP cohort only.
dSelf-reported exercise frequency during leisure time on a scale from 1–5, where 1: never; 2: every now and then - not regularly; 3: 1–2 times/week; 4: 2–3 times/week; 5: more than 3 times/week.
eSelf-reported on a scale from 1–5, where 1: sedentary or standing work; 2: light but partly physically active; 3: light and physically active; 4: sometimes physically strenuous; 5: physically strenuous most of the time.
fEstimated from self-administered, semi-quantitative food frequency questionnaires (FFQs) designed to measure intakes during the previous year in mass/day, divided by total energy intake.
Figure 2Bayesian network learning results (a) Bayesian network of plasma one-carbon metabolites divided into quartiles, related SNPs, and other environmental variables in relation to colorectal cancer (CRC) estimated with the HC algorithm. Analyses were made on 560 cases and 1090 controls (after excluding 53 cases and 100 controls with incomplete 1CM data). Edges in black were also present in IAMB and/or MMHC networks, whereas gray edges were present only in the HC network. Thicker edges indicate higher confidence (i.e., the frequency of the relation in the 1000 bootstrap networks). The estimated confidence thresholds for inclusion in the networks were: HC = 49%, IAMB = 50%, MMHC = 51%. The strongest independent associations with CRC risk, with edge confidences consistently higher compared to other variables for all algorithms, are marked with dashed edges. (b) Edge confidences of relations between CRC and 1CM variables for networks learned using the HC, IAMB, and MMHC algorithms. A higher edge confidence indicates a stronger independent association. Abbreviations: PA, physical activity; eGFR, estimated glomerular filtration rate; KTr, kynurenine/tryptophan ratio.
Figure 3Risk of CRC by vitamin B2 status.
Odds ratios (OR) were calculated by conditional logistic regression. Absolute risk differences (RD) were determined using weighted maximum likelihood estimation. Quartiles of plasma concentrations of vitamin B2 (riboflavin, nmol/l) were based on the distribution among the controls participants. Confidence intervals for the RDs were calculated by bootstrapping. Crude OR and RD estimates were adjusted only for the matching variables, using risk set stratification in conditional logistic regression and by including them as covariates in the weighted maximum likelihood models, respectively. Adjusted estimates were additionally adjusted for BMI, smoking status, occupational and recreational activity, alcohol intake, and plasma folate and vitamin B6 (PLP) concentrations. Ptrend was calculated by modeling log-transformed plasma concentrations in conditional logistic regression models.
Risk of CRC by vitamin B2 and B6 status.
| Vitamin B2 | Vitamin B6 | ||
|---|---|---|---|
| Tertile 1 (<30.8) | Tertile 2 (30.8–45.6) | Tertile 3 (≥45.6) | |
| Tertile 1 (<9.0) | |||
| Cases/controls (n) | 105/148 | 76/151 | 46/97 |
| OR-BN | ref | 0.78 | 0.80 |
| OR-CLR (95% CI) | ref | 0.70 (0.48, 1.02) | 0.67 (0.44, 1.04) |
| Tertile 2 (9.0–15.3) | |||
| Cases/controls (n) | 78/138 | 64/134 | 73/123 |
| OR-BN | 0.77 | 0.69 | 0.79 |
| OR-CLR (95% CI) | 0.78 (0.54, 1.14) | 0.66 (0.44, 0.99) | 0.83 (0.56, 1.21) |
| Tertile 3 (≥15.3) | |||
| Cases/controls (n) | 38/110 | 50/110 | 78/175 |
| OR-BN | 0.53 | 0.70 | 0.61 |
| OR-CLR (95% CI) | 0.48 (0.31, 0.75) | 0.63 (0.41, 0.97) | 0.62 (0.43, 0.90) |
| Pinteraction | |||
OR: Odds ratio - CI: Confidence interval - BN: Bayesian Network - CLR: conditional logistic regression – PLP: Pyridoxal 5′ phosphate.
aConcentrations in nmol/l, cut-offs based on the distribution of the controls.
bEstimated using fitted parameters of the estimated BN, additionally adjusted for the matching variables.
cEstimates from a CLR-model adjusted for the matching variables by risk set stratification. Adjusting for other potential confounders had essentially no effect on the estimates.
dCalculated by modeling log-transformed variables as multiplicative interaction terms in a CLR-model.